AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31686199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28617807 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus macrolide
Number of subjects: 106
Study 28617807 — intervention group
Group type: COMPARATOR
Intervention: Placebo with β-lactam plus macrolide
Number of subjects: 106
Study 28617807 — intervention group
Group type: COMPARATOR
Intervention: Placebo with β-lactam plus fluoroquinolone
Number of subjects: 106
Study 28617807 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus fluoroquinolone
Number of subjects: 106
Study 28617807 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality in the per protocol population
Number of subjects: 106
Study 28617807 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment failure
Number of subjects: 106
Study 25261629 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cTBS
Number of subjects: 29
Study 25261629 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 29
Study 23701738 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised CBT anger management intervention delivered by lay therapists
Number of subjects: 212
Study 21275080 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hydroxykynurenine (3-OHKY) levels
Number of subjects: 25
Study 21275080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptom scores
Number of subjects: 25
Study 21275080 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological symptoms
Number of subjects: 25
Study 21275080 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 25
Study 19713654 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stellate ganglion block with 8 ml 1% lidocaine solution
Number of subjects: 20
Study 17908769 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6‐174 G/G genotype
Number of subjects: 348
Study 17908769 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFA promoter genotypes ‐238 G/G and ‐376 G/G, TLR4 299 A/A genotype
Number of subjects: 348
Study 17908769 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFA‐238 G/G genotype or TNFA‐863 A allele carriage
Number of subjects: 348
Study 17908769 — intervention group
Group type: EXPERIMENTAL
Intervention: IL10‐1082 A/A genotype
Number of subjects: 348
Study 15531048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain patients
Number of subjects: 123
Study 15531048 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic participants
Number of subjects: 123
Study 11432712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed test kit
Number of subjects: 1000
Study 11432712 — intervention group
Group type: COMPARATOR
Intervention: Kit request card
Number of subjects: 1000
Study 11432712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed test kit with information leaflet
Number of subjects: 1000
Study 11432712 — intervention group
Group type: COMPARATOR
Intervention: Kit request card with information leaflet
Number of subjects: 1000
Study 9768403 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 60
Study 9768403 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual phacofracture
Number of subjects: 60
Study 7812483 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal subcutaneous needle
Number of subjects: 63
Study 7812483 — intervention group
Group type: COMPARATOR
Intervention: PTFE (Vialon) catheter
Number of subjects: 63
Study 7812483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 63
Study 7812483 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of medication injected per day
Number of subjects: 63
Study 2315771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium irrigation
Number of subjects: 0
Study 2315771 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 2315771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium irrigation
Number of subjects: 0
Study 340140 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid plus antispasmodic combination tablets (240 mg dried aluminium hydroxide, 144 mg magnesium hydroxide, 5 mg dicyclomine hydrochloride)
Number of subjects: 37
Study 340140 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide B.P. tablets (500 mg)
Number of subjects: 37
Study 31080025 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression with tranexamic acid
Number of subjects: 135
Study 31080025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing (Merocel)
Number of subjects: 135
Study 31080025 — intervention group
Group type: COMPARATOR
Intervention: Simple nasal external compression (saline solution)
Number of subjects: 135
Study 29714864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 100
Study 29714864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling (PVS)
Number of subjects: 100
Study 25310681 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed walking style
Number of subjects: 39
Study 25310681 — intervention group
Group type: COMPARATOR
Intervention: Happy walking style
Number of subjects: 39
Study 24100766 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior surgical approach (Post)
Number of subjects: 38
Study 24100766 — intervention group
Group type: COMPARATOR
Intervention: Antero-lateral surgical approach (AntLat)
Number of subjects: 38
Study 21663696 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at preferred intensity
Number of subjects: 38
Study 21663696 — intervention group
Group type: COMPARATOR
Intervention: Exercise at prescribed intensity
Number of subjects: 38
Study 19067057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure CO2 pneumoperitoneum
Number of subjects: 40
Study 19067057 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure CO2 pneumoperitoneum
Number of subjects: 40
Study 19067057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 17992378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment + brief psychological intervention (LSPI)
Number of subjects: 74
Study 17992378 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacological treatment (CT)
Number of subjects: 74
Study 17992378 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment + guidance program (OG)
Number of subjects: 74
Study 15095520 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injector/monitor device
Number of subjects: 15
Study 15095520 — intervention group
Group type: COMPARATOR
Intervention: Syringes and separate glucose monitor
Number of subjects: 15
Study 11028250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 11028250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg qd
Number of subjects: 76
Study 11028250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg qd
Number of subjects: 76
Study 11028250 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg qd
Number of subjects: 76
Study 11028250 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg tid
Number of subjects: 76
Study 11028250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg tid
Number of subjects: 76
Study 11028250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen 550 mg bid
Number of subjects: 76
Study 8746167 — intervention group
Group type: EXPERIMENTAL
Intervention: radioiodine therapy (aRIT)
Number of subjects: 53
Study 1326349 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (B) daily
Number of subjects: 22
Study 1326349 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (R) daily
Number of subjects: 22
Study 1326349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 22
Study 3912001 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (PGI2, 2‐8 ng kg‐1 min‐1)
Number of subjects: 6
Study 3912001 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐keto‐prostaglandin E1 (6‐keto‐PGE1, 7.5‐30 ng kg‐1 min‐1)
Number of subjects: 6
Study 31847914 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning levothyroxine (LT4) intake (60 min before breakfast)
Number of subjects: 91
Study 31847914 — intervention group
Group type: COMPARATOR
Intervention: Evening levothyroxine (LT4) intake (60 min after supper)
Number of subjects: 91
Study 31847914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and evening LT4 intake
Number of subjects: 91
Study 29893057 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated cartoons during ICS delivery
Number of subjects: 50
Study 29893057 — intervention group
Group type: COMPARATOR
Intervention: Black screen video during ICS delivery (Control)
Number of subjects: 50
Study 29893057 — intervention group
Group type: COMPARATOR
Intervention: Control (Black screen video)
Number of subjects: 50
Study 29893057 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated cartoons
Number of subjects: 50
Study 26701116 — intervention group
Group type: EXPERIMENTAL
Intervention: FATmax training (exercise training at individualized FATmax intensities, 1 h per day, 5 days per week for 10 weeks)
Number of subjects: 26
Study 26701116 — intervention group
Group type: EXPERIMENTAL
Intervention: FATmax training
Number of subjects: 26
Study 26701116 — intervention group
Group type: COMPARATOR
Intervention: Control group (lean boys)
Number of subjects: 26
Study 24847745 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/d
Number of subjects: 3109
Study 24847745 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/d
Number of subjects: 3109
Study 24847745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3109
Study 22265923 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50mg every day for 5 days (days 3-7 of cycle)
Number of subjects: 750
Study 22265923 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5mg every day for 5 days (days 3-7 of cycle)
Number of subjects: 750
Study 19496398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% citric acid-3% ferric chloride (10-3)
Number of subjects: 3
Study 19496398 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% phosphoric acid (PA)
Number of subjects: 3
Study 19496398 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 3
Study 17601060 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% carteolol hydrochloride long-acting eye drops (instilled once a day in the morning for 8 weeks)
Number of subjects: 146
Study 17601060 — intervention group
Group type: COMPARATOR
Intervention: 1% carteolol hydrochloride currently-prescribed eye drops (instilled twice a day for 8 weeks)
Number of subjects: 146
Study 15743368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic lecture (DL) + Interactive case-based seminar (ICBS) + PDA-based risk assessment tool
Number of subjects: 82
Study 15743368 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture (DL)
Number of subjects: 82
Study 15743368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic lecture (DL) + Interactive case-based seminar (ICBS)
Number of subjects: 82
Study 12516683 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin sodium 3500 anti-Xa IU per day (group A)
Number of subjects: 65
Study 12516683 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin sodium 4200 anti-Xa IU per day (group B)
Number of subjects: 65
Study 12516683 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin sodium 5950 anti-Xa IU per day (group C)
Number of subjects: 65
Study 12516683 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin sodium 7000 anti-Xa IU per day (group D)
Number of subjects: 65
Study 9524995 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based educational intervention
Number of subjects: 2004
Study 9524995 — intervention group
Group type: COMPARATOR
Intervention: Regular clinic services (Control)
Number of subjects: 2004
Study 9524995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk intervention group
Number of subjects: 2004
Study 9524995 — intervention group
Group type: COMPARATOR
Intervention: High-risk controls (Control)
Number of subjects: 2004
Study 7657280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol (10 to 12 mg/kg at bedtime for 2 years)
Number of subjects: 151
Study 7657280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 151
Study 7657280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 2651175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine-pentoxifylline combination
Number of subjects: 79
Study 2651175 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-dipyridamole-buflomedil
Number of subjects: 79
Study 2651175 — intervention group
Group type: COMPARATOR
Intervention: Buflomedil-placebo
Number of subjects: 79
Study 778563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon)
Number of subjects: 0
Study 31654328 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib extended-release formulations (four different formulations)
Number of subjects: 20
Study 31654328 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib immediate-release capsule formulation
Number of subjects: 20
Study 31654328 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation formulation
Number of subjects: 20
Study 31654328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation model
Number of subjects: 20
Study 28026912 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg once daily
Number of subjects: 219
Study 28026912 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 219
Study 25795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferring medications
Number of subjects: 740
Study 25795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickness absence
Number of subjects: 740
Study 25795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Being referred to a physiotherapist/chiropractor
Number of subjects: 740
Study 25795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing their lifestyle
Number of subjects: 740
Study 25795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Wanting to keep living as usual only
Number of subjects: 740
Study 23632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-home exercise intervention (training for care home staff and twice-weekly physiotherapist-led exercise group)
Number of subjects: 1054
Study 23632142 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (depression awareness training programme for care home staff)
Number of subjects: 1054
Study 23632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-home exercise intervention
Number of subjects: 1054
Study 21277231 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1500 mg daily divided in two doses for 12 weeks
Number of subjects: 16
Study 21277231 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 16
Study 19454839 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg EMIQ for 8 weeks
Number of subjects: 24
Study 19454839 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 24
Study 17291170 — intervention group
Group type: COMPARATOR
Intervention: Internet-only treatment
Number of subjects: 123
Study 17291170 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet + in-person support (I+IPS)
Number of subjects: 123
Study 17291170 — intervention group
Group type: COMPARATOR
Intervention: Internet-only treatment (completers)
Number of subjects: 123
Study 17291170 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet + in-person support (I+IPS) (completers)
Number of subjects: 123
Study 15289593 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating The Blues plus conventional care
Number of subjects: 48
Study 15289593 — intervention group
Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 48
Study 10944552 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest x-ray and sputum cytology every 4 months for 6 years
Number of subjects: 9211
Study 10944552 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm (advised to receive tests annually)
Number of subjects: 9211
Study 9072981 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 30% of peak maximal inspiratory pressure (PI,max) for 30 min daily, 6 days a week for 10 weeks
Number of subjects: 20
Study 9072981 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT) at 10% of peak maximal inspiratory pressure (PI,max) for 30 min daily, 6 days a week for 10 weeks
Number of subjects: 20
Study 8452171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin, 400 mg intravenously once a day
Number of subjects: 319
Study 8452171 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime, 0.5‐2 g three times daily or 1‐2 g twice daily
Number of subjects: 319
Study 3528241 — intervention group
Group type: EXPERIMENTAL
Intervention: squaric acid dibutylester
Number of subjects: 119
Study 3528241 — intervention group
Group type: EXPERIMENTAL
Intervention: diphencyprone
Number of subjects: 119
Study 3528241 — intervention group
Group type: EXPERIMENTAL
Intervention: minoxidil
Number of subjects: 119
Study 3528241 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 119
Study 31506186 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific osteosynthesis
Number of subjects: 58
Study 31506186 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteosynthesis and splint-based positioning
Number of subjects: 58
Study 29482662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 330
Study 29482662 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EI)
Number of subjects: 330
Study 29482662 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 330
Study 29482662 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 330
Study 29037651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression (4 sessions)
Number of subjects: 19
Study 26215765 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of systolic blood pressure (SBP) defined as SD across SBP measurements (≥14.4 mm Hg)
Number of subjects: 25814
Study 26215765 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of diastolic blood pressure (DBP)
Number of subjects: 25814
Study 24040947 — intervention group
Group type: EXPERIMENTAL
Intervention: A100 1.8 mL
Number of subjects: 30
Study 24040947 — intervention group
Group type: EXPERIMENTAL
Intervention: A100 3.6 mL
Number of subjects: 30
Study 20829043 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual digital mammography with MRI
Number of subjects: 348
Study 20829043 — intervention group
Group type: COMPARATOR
Intervention: Annual digital mammography without MRI
Number of subjects: 348
Study 18815979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 14
Study 16549077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon distension of the fundus (0, 400, 600, 800 ml) before a standard meal intake
Number of subjects: 24
Study 16549077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon distension of the antrum (0 ml plus ID saline or ID fat, and 300 ml plus ID saline or ID fat)
Number of subjects: 24
Study 12888872 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin (8000 U anti-factor Xa, subcutaneous, twice daily for 10 to 14 days)
Number of subjects: 1220
Study 12888872 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, intravenous, aPTT-adjusted for 5 to 8 days)
Number of subjects: 1220
Study 12888872 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin
Number of subjects: 1220
Study 12888872 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 1220
Study 10366166 — intervention group
Group type: EXPERIMENTAL
Intervention: High collar shoes
Number of subjects: 42
Study 10366166 — intervention group
Group type: COMPARATOR
Intervention: College shoes
Number of subjects: 42
Study 10366166 — intervention group
Group type: COMPARATOR
Intervention: Soft-soled shoes
Number of subjects: 42
Study 10366166 — intervention group
Group type: COMPARATOR
Intervention: Hard-soled shoes
Number of subjects: 42
Study 10366166 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 42
Study 8737135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 0
Study 8737135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1957404 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum albumin (hSA) 200 mg/ml
Number of subjects: 135
Study 1957404 — intervention group
Group type: COMPARATOR
Intervention: Patient serum
Number of subjects: 135
Study 7181489 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 10
Study 7181489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 10
Study 31393225 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric gluten-free diet (GFD) for 6 months
Number of subjects: 60
Study 31393225 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric diet (CG)
Number of subjects: 60
Study 31594736 — intervention group
Group type: COMPARATOR
Intervention: Single intravesical instillation (SIC) with epirubicin 50 mg
Number of subjects: 74
Study 31594736 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance intravesical chemotherapy (MIC) once weekly for 6 weeks plus once monthly for 1 year
Number of subjects: 74
Study 31594736 — intervention group
Group type: COMPARATOR
Intervention: Single intravesical instillation (SIC)
Number of subjects: 74
Study 31594736 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance intravesical chemotherapy (MIC)
Number of subjects: 74
Study 27785737 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib (25-1200 mg; fasted) as single or twice-daily oral doses for 7 days
Number of subjects: 120
Study 27785737 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib (≥600 mg twice daily)
Number of subjects: 120